Charles River Laboratories International Inc. (CRL): Price and Financial Metrics
CRL Price/Volume Stats
| Current price | $229.03 | 52-week high | $275.00 |
| Prev. close | $227.81 | 52-week low | $161.65 |
| Day low | $227.39 | Volume | 322,100 |
| Day high | $230.86 | Avg. volume | 551,216 |
| 50-day MA | $252.97 | Dividend yield | N/A |
| 200-day MA | $216.48 | Market Cap | 11.80B |
CRL Stock Price Chart Interactive Chart >
Charles River Laboratories International Inc. (CRL) Company Bio
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. (Source:Wikipedia)
Latest CRL News From Around the Web
Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?Charles River Laboratories International, Inc. ( NYSE:CRL ) led the NYSE gainers with a relatively large price hike in... |
Charles River's (CRL) Memphis Site Achieves Crucial ApprovalCharles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals. |
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing CollaborationWILMINGTON, Mass. & MEMPHIS, Tenn., December 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]). CASGEVY is approved in some countries for certain eligible patients. |
Charles River (CRL) Expands 3D In Vitro Services Via New DealCharles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics. |
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug ScreeningWILMINGTON, Mass. & BERLIN, December 12, 2023--Charles River expands portfolio of 3D in vitro testing services for oncology research with CELLphenomics' proprietary PD3D tumor model platform. |
CRL Price Returns
| 1-mo | -15.47% |
| 3-mo | 3.97% |
| 6-mo | 39.21% |
| 1-year | 20.47% |
| 3-year | -31.59% |
| 5-year | 60.70% |
| YTD | -3.12% |
| 2023 | 8.49% |
| 2022 | -42.17% |
| 2021 | 50.80% |
| 2020 | 63.56% |
| 2019 | 34.97% |
Continue Researching CRL
Want to do more research on Charles River Laboratories International Inc's stock and its price? Try the links below:Charles River Laboratories International Inc (CRL) Stock Price | Nasdaq
Charles River Laboratories International Inc (CRL) Stock Quote, History and News - Yahoo Finance
Charles River Laboratories International Inc (CRL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...